Skip to main content
NVDA-2.26%AAPL+3.21%GOOGL+0.77%MSFT-0.04%AMZN-0.40%TSM-1.36%SPCX+0.37%AVGO-0.72%META-1.33%TSLA-1.04%SKHY-4.44%MU-4.49%BRK-B0.00%LLY+0.20%JPM-0.48%WMT-0.02%AMD-3.11%V-0.12%XOM+0.79%ASMLa-1.66%JNJ-0.20%INTC-5.00%MA-0.45%0700.HK-1.94%1398.HK+0.79%ORCL-4.82%ABBV+1.36%BAC-0.30%CSCO-1.41%CVX-0.30%COST-0.12%KO+0.49%LRCX-5.25%CAT-1.33%AP2d-1.55%0005.HK-0.78%AMAT-2.77%UNH-0.89%HSBA.L-1.30%DELL-4.01%PG+0.19%MS-1.04%GE-0.53%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.14%HD-1.74%0939.HK+1.66%GS-1.17%NZDJPY-2.63%AUDJPY-1.87%CHFJPY-1.61%NZDCAD-1.45%EURNZD+1.43%NZDUSD-1.42%GBPNZD+1.37%GBPJPY-1.26%EURJPY-1.25%USDJPY-1.24%CADJPY-1.20%NZDCHF-1.05%USDZAR+1.04%USDSEK+0.95%USDNOK+0.90%EURZAR+0.85%AUDNZD+0.79%GBPZAR+0.76%EURSEK+0.76%EURNOK+0.71%USDTHB+0.70%AUDCAD-0.70%AUDDKK-0.66%AUDUSD-0.64%EURAUD+0.63%CHFSEK+0.60%GBPAUD+0.59%USDMXN+0.58%CHFNOK+0.56%AUDSGD-0.56%USDPLN+0.45%GBPTRY+0.41%NZDSGD-0.41%CADCHF+0.40%USDCHF+0.39%NOKJPY-0.39%EURCHF+0.36%GBPCHF+0.33%GBPHKD+0.32%USDSGD+0.29%GBPMXN-0.28%EURPLN+0.26%AUDCHF-0.26%SGDJPY+0.22%EURHKD-0.19%USDDKK+0.19%USDILS+0.16%NZDMXN-0.13%USDTRY+0.11%USDCNH+0.10%EURSGD+0.10%GBPCAD-0.09%EURCNH-0.06%PLNJPY+0.06%AUDNOK+0.06%EURCZK-0.06%CHFSGD-0.05%EURCAD-0.05%EURGBP+0.04%USDCOP-0.04%GBPUSD-0.04%USDCAD-0.02%EURUSD-0.02%USDHKD+0.02%GBPSGD+0.01%EURDKK0.00%XPTUSD-6.18%UKOIL+5.85%USOIL+5.68%GAGUSD-5.47%XAGUSD-5.47%HG1-4.85%XAUUSD-1.74%GAUUSD-1.74%XNGUSD+1.59%SUGAR0.00%S10.00%COFFEE0.00%BTCUSD-1.36%ETHUSD-0.01%USDTUSD-0.02%XRPUSD-2.86%SOLUSD-1.55%TRXUSDT+0.21%ZECUSDT-9.15%DOGEUSD-2.40%XMRUSDT+0.31%LINKUSD-1.28%XLMUSD-1.47%BCHUSDT-9.71%LTCUSD-1.65%UNIUSD-0.88%TONUSD+24.88%HBARUSDT-2.05%SUIUSD-4.19%TAOUSDT-5.53%AAVEUSD-1.81%DOTUSDT-1.74%ICPUSDT-0.47%ONDOUSDT-3.29%WLDUSDT-3.39%ATOMUSDT-3.00%ARBUSDT-0.64%JUPUSDT-3.39%INJUSDT-2.11%STXUSDT-4.53%FETUSDT-2.80%TIAUSDT-1.13%PYTHUSDT-1.22%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-3.61%WIFUSDT-4.89%OPUSDT-4.00%POLUSDT-4.54%IOTAUSDT-4.02%AXSUSDT-2.25%FARTCOINUSDT-2.66%EOSUSDT-2.78%DYDXUSDT-2.47%ORDIUSDT-0.86%GALAUSDT-3.09%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.26%AAPL+3.21%GOOGL+0.77%MSFT-0.04%AMZN-0.40%TSM-1.36%SPCX+0.37%AVGO-0.72%META-1.33%TSLA-1.04%SKHY-4.44%MU-4.49%BRK-B0.00%LLY+0.20%JPM-0.48%WMT-0.02%AMD-3.11%V-0.12%XOM+0.79%ASMLa-1.66%JNJ-0.20%INTC-5.00%MA-0.45%0700.HK-1.94%1398.HK+0.79%ORCL-4.82%ABBV+1.36%BAC-0.30%CSCO-1.41%CVX-0.30%COST-0.12%KO+0.49%LRCX-5.25%CAT-1.33%AP2d-1.55%0005.HK-0.78%AMAT-2.77%UNH-0.89%HSBA.L-1.30%DELL-4.01%PG+0.19%MS-1.04%GE-0.53%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.14%HD-1.74%0939.HK+1.66%GS-1.17%NZDJPY-2.63%AUDJPY-1.87%CHFJPY-1.61%NZDCAD-1.45%EURNZD+1.43%NZDUSD-1.42%GBPNZD+1.37%GBPJPY-1.26%EURJPY-1.25%USDJPY-1.24%CADJPY-1.20%NZDCHF-1.05%USDZAR+1.04%USDSEK+0.95%USDNOK+0.90%EURZAR+0.85%AUDNZD+0.79%GBPZAR+0.76%EURSEK+0.76%EURNOK+0.71%USDTHB+0.70%AUDCAD-0.70%AUDDKK-0.66%AUDUSD-0.64%EURAUD+0.63%CHFSEK+0.60%GBPAUD+0.59%USDMXN+0.58%CHFNOK+0.56%AUDSGD-0.56%USDPLN+0.45%GBPTRY+0.41%NZDSGD-0.41%CADCHF+0.40%USDCHF+0.39%NOKJPY-0.39%EURCHF+0.36%GBPCHF+0.33%GBPHKD+0.32%USDSGD+0.29%GBPMXN-0.28%EURPLN+0.26%AUDCHF-0.26%SGDJPY+0.22%EURHKD-0.19%USDDKK+0.19%USDILS+0.16%NZDMXN-0.13%USDTRY+0.11%USDCNH+0.10%EURSGD+0.10%GBPCAD-0.09%EURCNH-0.06%PLNJPY+0.06%AUDNOK+0.06%EURCZK-0.06%CHFSGD-0.05%EURCAD-0.05%EURGBP+0.04%USDCOP-0.04%GBPUSD-0.04%USDCAD-0.02%EURUSD-0.02%USDHKD+0.02%GBPSGD+0.01%EURDKK0.00%XPTUSD-6.18%UKOIL+5.85%USOIL+5.68%GAGUSD-5.47%XAGUSD-5.47%HG1-4.85%XAUUSD-1.74%GAUUSD-1.74%XNGUSD+1.59%SUGAR0.00%S10.00%COFFEE0.00%BTCUSD-1.36%ETHUSD-0.01%USDTUSD-0.02%XRPUSD-2.86%SOLUSD-1.55%TRXUSDT+0.21%ZECUSDT-9.15%DOGEUSD-2.40%XMRUSDT+0.31%LINKUSD-1.28%XLMUSD-1.47%BCHUSDT-9.71%LTCUSD-1.65%UNIUSD-0.88%TONUSD+24.88%HBARUSDT-2.05%SUIUSD-4.19%TAOUSDT-5.53%AAVEUSD-1.81%DOTUSDT-1.74%ICPUSDT-0.47%ONDOUSDT-3.29%WLDUSDT-3.39%ATOMUSDT-3.00%ARBUSDT-0.64%JUPUSDT-3.39%INJUSDT-2.11%STXUSDT-4.53%FETUSDT-2.80%TIAUSDT-1.13%PYTHUSDT-1.22%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-3.61%WIFUSDT-4.89%OPUSDT-4.00%POLUSDT-4.54%IOTAUSDT-4.02%AXSUSDT-2.25%FARTCOINUSDT-2.66%EOSUSDT-2.78%DYDXUSDT-2.47%ORDIUSDT-0.86%GALAUSDT-3.09%NOTUSDT-2.97%RONINUSDT-2.64%
EP

Eton Pharmaceuticals, Inc. (ETON)

NASDAQ • Healthcare

$58.83
-$0.52 (-0.9%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$58.91
Previous Close$58.83
Day Range$58.66 - $60.43
Avg. Volume (3M)699.4K
Market Cap$1.5B
P/E Ratio125.2
52 Week Range
$14.27$66.37
Next EarningsIn 56 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$37.5M100%
Gross Profitminus cost of goods$25.4M68%
Operating Incomeminus R&D and overhead$12.7M34%
Net Incomeminus taxes and the rest$11.5M31%

In plain terms: out of every $100 in revenue, Eton Pharmaceuticals, Inc. keeps $31 as net profit.

Fundamentals & Financials

Revenue (TTM)
$105.5M
Net Income (TTM)
$12.6M
EPS (TTM)
$0.47
ROA (TTM)
10.96%
Current Ratio
1.52
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-58.3%Q1 2026$0.05
-50.0%Q2 2026$0.05
+126.6%Q3 2026$0.43
Next

Nov 5

in 56 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +126.6%

Revenue nearly doubled year over year in Eton Pharmaceuticals’ second fiscal quarter of 2026, with sales up 98.6% to about $37.6 million (from roughly $18.9 million a year ago) in results reported August 13, 2026, reflecting continued contribution from its rare-disease commercial portfolio across endocrine, metabolic, and liver-related disorders. Profitability at the gross line was reflected in gross profit of about $25.4 million, putting gross margin at ~68% for the quarter. The company also generated operating cash flow of about $7.3 million. Consensus for the next period calls for EPS of $0.34 on revenue of $42.0 million.

View full earnings history

About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) develops and commercializes rare-disease medicines as a specialty pharmaceutical company, with $80.0 million in FY2025 revenue. Its marketed portfolio spans endocrine, metabolic, and liver-related disorders, and includes products for severe primary IGF-1 deficiency, adrenal disorders, Wilson disease, phenylketonuria, homocystinuria, and tyrosinemia type 1.

Name
Eton Pharmaceuticals, Inc.
CEO
Sean E. Brynjelsen
Website
www.etonpharma.com
Industry
Healthcare
Year Founded
2017
Employees
44

Today's Snapshot

AI-generated

So far today, ETON is trading 1.3% lower at 58.08, in line with a weaker sector.

Trading Volume

Below 10d avg (487.7K)

144.4K

vs S&P 500 Today

Underperforming Market

-0.66%

Updated: September 10, 2026 at 19:33 UTC

Technical Indicators

4 Buy3 Neutral1 Sell
ETON is changing hands at 57.79 and shows a buy stance driven by a well-established longer-term uptrend alongside short-term mixed signals. ADX just above 34 indicates trend strength, and while momentum measures are mixed — MACD positive but short-term momentum negative — the stock remains above the 50-, 100- and 200-day averages even as it sits slightly below the shortest moving averages and under VWAP. Volatility is elevated with ATR near 3.10 and OBV is soft. Technical takeaway: Buy — longer-term trend remains intact despite short-term pressure and muted volume.
All signals
  • EMA (5 indicators)$32.84 - $59.36
    Buy
  • RSI (14)54.60
    Neutral
  • Stochastic %K (14, 3, 3)25.06
    Neutral
  • MACD Level (12, 26)2.96
    Neutral

Peers & Related Assets

OMEROmeros Corporation
$19.39+1.4%
FULCFulcrum Therapeutics, Inc.
$3.84+0.5%
ADCTADC Therapeutics S.A.
$1.22-6.2%
RAPTRAPT Therapeutics, Inc.
LXRXLexicon Pharmaceuticals, Inc.
MNPRMonopar Therapeutics Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.